นโยบายงานวิจัย /จรรยาบรรณนักวิจัย /ระดับคุณภาพบทความวิจัยตีพิมพ์ /ระดับคุณภาพผลงานวิชาการ /แหล่งทุน /ดาวน์โหลด /ฐานข้อมูลวิจัย /วิเคราะห์-สังเคราะห์งานวิจัย /ลิขสิทธิ์ /ข่าว


ยาใหม่หรับภาวะโรคจิตในโรคพาร์กินสัน : Pimavanserin


Author

-

ทวนธน บุญลือ


Journal

- วารสารเภสัชศาสตร์อีสาน

Volume

- 14

Year

- 2018

Publication type

- Review article (National)

Page list

- 26

Abstract

   

Parkinson’s disease psychosis (PDP) is a common problem in late stage of Parkinson’s disease. Patients with Parkinson’s disease psychosis usually present with visual hallucinations and delusions. The prevalence of Parkinson’s disease psychosis shows in a half of patients with Parkinson’s disease. The consequence of Parkinson’s disease psychosis affects both patients and caregivers. For patients with diagnosed of PDP, the increased risk of morbidity and mortality can occur and also decrease caregiver’s quality of life. The diagnosis of Parkinson’s disease psychosis following The National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS) criteria that patient should has one of illusion, false sense of presence, hallucinations or delusion and the symptoms must occur after received diagnosis of Parkinson’s disease. The recommendation for management of Parkinson’s disease psychosis is using clozapine because the drug possess less effect on movement system. However, the use of clozapine should monitor for serious life threatening side effects. The developing medications for Parkinson’s disease psychosis has their own mechanism beyond dopaminergic system modification. Pimavanserin, 5-HT2A inverse agonist, has good efficacy and safety in patients with Parkinson’s disease psychosis. In 6-weeks clinical trial, pimavanserin could decrease Parkinson’s disease-adapted scale for assessment of positive symptoms (SAPS-PD) score better than placebo with no difference in term of adverse events. The US Food and Drug Administration (FDA) has been approved pimavanserin, the first agent in the class of drug for Parkinson’s disease psychosis in the dose of 34 mg per day. However, long term effectiveness, safety and economic evaluations of pimavanserin still require more data using in clinical practice.
 


Keywords

   

Parkinson’s disease psychosis, pimavanserin, clozapine